Rage Biotech
Melbourne, Australia· Est.
Rage Biotech leverages splice‑switching oligonucleotides to reprogram RAGE signaling for novel anti‑inflammatory therapies.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Rage Biotech leverages splice‑switching oligonucleotides to reprogram RAGE signaling for novel anti‑inflammatory therapies.
InflammationImmunology
Technology Platform
Splice‑switching oligonucleotides (SSOs) that reprogram RAGE pre‑mRNA splicing to shift the balance from pro‑inflammatory to anti‑inflammatory isoforms.
Opportunities
Successful IND filing and early‑phase clinical data could attract strategic partnerships or acquisition interest from larger pharma seeking novel anti‑inflammatory modalities.
Risk Factors
Reliance on a single therapeutic target and the inherent challenges of RNA delivery may delay development timelines and increase technical risk.
Competitive Landscape
Rage Bio’s focus on RAGE splice modulation differentiates it from broader RNA‑therapeutics companies, but it must compete with established antisense and small‑molecule anti‑inflammatory pipelines.